Zacks Investment Research cut shares of Aquinox Pharmaceuticals (NASDAQ:AQXP) from a buy rating to a hold rating in a report released on Friday.
According to Zacks, “Aquinox Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. The Company discovers and develops oral drug candidates to treat inflammation and cancer. Aquinox Pharmaceuticals, Inc. is headquartered in Vancouver, Canada. “
Other research analysts have also recently issued research reports about the company. Canaccord Genuity set a $22.00 price target on Aquinox Pharmaceuticals and gave the stock a buy rating in a research note on Tuesday, December 19th. Needham & Company LLC reiterated a buy rating and issued a $25.00 price target on shares of Aquinox Pharmaceuticals in a research note on Thursday, November 9th. Cantor Fitzgerald reiterated a buy rating and issued a $28.00 price target on shares of Aquinox Pharmaceuticals in a research note on Thursday, November 9th. Finally, ValuEngine cut Aquinox Pharmaceuticals from a hold rating to a sell rating in a research note on Friday, September 15th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and three have issued a buy rating to the company’s stock. The company has a consensus rating of Hold and a consensus target price of $22.00.
Several large investors have recently added to or reduced their stakes in AQXP. Nexthera Capital LP acquired a new position in shares of Aquinox Pharmaceuticals in the second quarter worth about $1,276,000. University of Notre Dame DU Lac increased its holdings in Aquinox Pharmaceuticals by 11.1% in the third quarter. University of Notre Dame DU Lac now owns 190,283 shares of the company’s stock valued at $2,700,000 after buying an additional 19,066 shares during the last quarter. Vanguard Group Inc. increased its holdings in Aquinox Pharmaceuticals by 6.6% in the second quarter. Vanguard Group Inc. now owns 282,483 shares of the company’s stock valued at $3,974,000 after buying an additional 17,455 shares during the last quarter. Citadel Advisors LLC bought a new stake in Aquinox Pharmaceuticals in the third quarter valued at about $194,000. Finally, Sphera Funds Management LTD. increased its holdings in Aquinox Pharmaceuticals by 21.7% in the third quarter. Sphera Funds Management LTD. now owns 75,535 shares of the company’s stock valued at $1,072,000 after buying an additional 13,450 shares during the last quarter. Institutional investors and hedge funds own 96.25% of the company’s stock.
TRADEMARK VIOLATION WARNING: This report was first posted by Week Herald and is the property of of Week Herald. If you are reading this report on another publication, it was illegally copied and reposted in violation of international trademark and copyright law. The original version of this report can be read at https://weekherald.com/2018/01/13/aquinox-pharmaceuticals-aqxp-downgraded-by-zacks-investment-research-to-hold.html.
Aquinox Pharmaceuticals Company Profile
Aquinox Pharmaceuticals, Inc is a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology. The Company’s primary focus is anti-inflammatory product candidates targeting the Src Homology 2 (SH2)-containing inositol-5-phosphatase 1 (SHIP1) enzyme, which is a regulator of a cellular signaling pathway in immune cells, known as the phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K) pathway.
Receive News & Ratings for Aquinox Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aquinox Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.